Dual Therapy Effective At Maintaining Undetectable Viral Load Of HIV Patients Who Switch From NRTIs, Study Suggests.

MedPage Today (10/10, Highleyman) reports research presented at a meeting during the annual IDWeek conference suggests “dolutegravir (Tivicay) plus boosted darunavir (Prezista) maintained undetectable viral load in more than 90%” of HIV patients “who wis...